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1. Introduction 
 
- Breast cancer is the most common malignancy among females and the 
leading cause of cancer death in relation to women.  
 
- Male breast cancer (MBC) is rare accounting for <1% of all breast 
cancer cases and its prevalence increases with age.  
 
- About 5-10% of breast cancer cases are hereditary and are caused by 
pathogenic mutations in BRCA1 and BRCA2 genes.  
 
- BRCA1 mutations are more common in female breast cancer whereas 
male breast cancer is characterized by BRCA2 mutations although 
women can have BRCA2 mutations and men BRCA1 mutations.  
 
- There are some different types of treatment for men with breast cancer 
like surgery, chemotherapy, radiotherapy and more others.  
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3. Male Breast Cancer 
 
- Male breast cancer (MBC) is rare in contrast to female breast cancer 
and this has been reflected in research.  It has an Incidence rate of 
0.5/100000 men per year, 0.1% of male cancer deaths.  
 
- Usually appears in men 60 to 70 years.  
 
- Risk factors:  
 Gynecomastia 
 Testicular conditions 
 Klinefelter syndrome 
- Inherited mutations in BRCA also increase the risk of MBC and it 
appears to be higher with inherited BRCA2 rather than BRCA1 
mutations.   
 
- There are 5 stages of MBC. 
4. Genes and signalling pathways involved  
 
- Approximately, a 45% of families with hereditary breast cancer have 
mutations in BRCA genes.  
 
- Hereditary breast cancer occurs in families in which there are some 
family members affected of different generations.  
 
- Only 5% of all hereditary breast cancer are due to BRCA1 and BRCA2 
mutations.  
 
- Male BRCA2 mutations carriers confer a lifetime risk of breast cancer 
(6%). 
 
- BRCA2 related tumors usually express estrogen and progesterone 
receptors.  
Fig 1. Genes involved in hereditary breast cancer. Cell Oncol (Dordr) 2011 April; 34(2): 
71–88. Published online 2011 February 19. doi: 10.1007/s13402-011-0010-3  
5. Diagnosis 
5. Differences between Male and Female 
6. Treatment  
 
- Some of the treatments are standards and very similar to those used in 
women while others are being tested in clinical trials.Patient 
participation in clinical trials are often the best way to treat cancer and 
should take into account when choosing the treatment.  
 
- Breast cancer treatment is divided in 3 groups according to the 
disease stage: 
2. Material and Methods  
 
- Literature research using mainly three free databases: Medline 
Pubmed, Uptodate and Elsevier. The parameters or the key words 
sought were:   
- Breast cancer 
- Male  
- Hereditary  
 Male breast cancer is rare compared to female 
 
 Only 5-10% of breast cancer are hereditary 
 
 Risk factors like gynecomastia can cause male breast cancer. 
CONCLUSIONS 
Clinical diagnosis - Mammography 
- Biopsy  
Differential diagnosis Includes gynecomastia, breast abscess, metastases to the 
breast and other non-breast cancer primary tumors.  
Molecular diagnosis of BRCA1 
and BRCA2 genes 
- Targeted mutation analysis  
- Sequence analysis  
- Deletion/duplication analysis 
Table 1. Diagnosis for MBC. 
Characteristics MBC 
  
FBC 
Incidence rate 0.5-1/100000 men per year 1-4 million of annual new cases  
Main gene mutation BRCA2 BRCA1 
  
Estrogen receptor or 
progesterone receptor  
90% of MBC 60-70% of FBC 
  
Prognosis 
  
Worse due to older age and 
more advanced disease stage 
at diagnosis 
  
Better due to early age of diagnosis 
  
Treatment 
  
Mastectomy as main treatment 
  
Mastectomy as main treatment 
Table 2. Differences between Male and Female.  
* MBC (Male Breast Cancer), FBC (Female Breast Cancer). 
Treatment for early 
stage localized 
disease 
Treatment of locally 
advanced disease 
Treatment of 
advanced disease 
Surgery 
Chemotherapy 
Radiotherapy 
Hormone Therapy 
Chemotherapy 
Hormone Therapy 
 BRCA2 affects 40% of men with breast cancer 
 
 The diagnosis is essential when there is suspicion of breast cancer. 
 
 Treatment is similar in male and female.  
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